Home » Targacept Begins Trial of Candidate for Neuropathic Pain
Targacept Begins Trial of Candidate for Neuropathic Pain
Targacept has started a Phase I trial of neuropathic pain candidate TC-6499.
The double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of TC-6499.
The initiation of the trial triggers a $6 million milestone payment to Targacept under the terms of its agreement with GlaxoSmithKline. Targacept said it is eligible to receive an additional milestone payment if it advances TC-6499 to Phase II.
Upcoming Events
-
07May
-
14May
-
30May